Archive

Aegerion Pharmaceuticals Will Pay More Than $40 Million to Resolve Investigations Into Its Marketing and Sales Practices

Posted 09/25/17

Aegerion Pharmaceuticals will plead guilty to charges concerning its prescription drug, Juxtapid, the Department of Justice announced on Friday. According to the Justice Department’s press release: Aegerion introduced Juxtapid into interstate commerce that was misbranded because, among other things, Aegerion failed to comply with a Risk Evaluation and Mitigation Strategy (REMS). The resolution also...

Tagged in: FCA Federal, FDA Fraud, Pharma Fraud, Securities Fraud, Whistleblower Case, Whistleblower Rewards,

Health Insurers May Be Contributing to the Opioid Crisis in the United States

Posted 09/18/17

By the C|C Whistleblower Lawyer Team An article in the New York Times describes the role health insurers may be playing in perpetuating the opioid crisis in the United States. The argument is that health insurers are limiting access to pain medications that have a lower risk of dependency. The reason is that opioid drugs are generally cheaper and less risky alternatives are more expensive. The New York State...

Tagged in: Healthcare Fraud, Pharma Fraud,

DOJ Catch of the Week -- Novo Nordisk Inc.

Posted 09/8/17

By the C|C Whistleblower Lawyer Team This week's Department of Justice "Catch of the Week" goes to Novo Nordisk Inc. On Tuesday, the company agreed to pay $58.65 million to settle charges it violated the False Claims Act and Food, Drug, and Cosmetic Act by failing to comply with the FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) for its Type II diabetes medication Victoza. The New Jersey based...

Tagged in: Catch of the Week, FCA Federal, FDA Fraud, Pharma Fraud,

Mylan Agrees to Pay $465 Million in a False Claims Act Settlement

Posted 08/21/17

By the C|C Whistleblower Lawyer Team Last Friday, the Department of Justice (“DOJ”) announced a $465 million settlement with Mylan, Inc. to resolve claims that it violated the False Claim Act. The suit was brought by a whistleblower under the False Claims Act qui tam provisions and involved the alleged improper misclassification of the EpiPen as a generic drug to avoid paying rebates owed mainly to Medicaid....

Tagged in: Drug and DME Pricing, Medicaid, Pharma Fraud, Whistleblower Case, Whistleblower Eligibility, Whistleblower Rewards,

DOJ Catch of the Week -- Mylan

Posted 08/18/17

By the C|C Whistleblower Lawyer Team This week's Department of Justice "Catch of the Week" goes to Mylan Inc. and Mylan Specialty L.P. Yesterday, the pharmaceutical companies agreed to pay $465 million to settle charges they violated the False Claims Act by purposely misclassifying EpiPen as a generic drug to avoid paying higher Medicaid rebates. In announcing the settlement, the government stressed its "unwavering...

Tagged in: Catch of the Week, Drug and DME Pricing, FCA Federal, Medicaid, Pharma Fraud, Whistleblower Eligibility, Whistleblower Rewards,

Martin Shkreli is Found Guilty of Fraud

Posted 08/7/17

By the C|C Whistleblower Lawyer Team A recent New York Times story details the reaction to a federal jury finding Martin Shkreli guilty on three counts of fraud. Shkreli faces up to twenty years in prison for each of the first two counts and five years in prison on the final count with sentencing pending. The jury spent five days deliberating before coming to its three guilty verdicts and acquitting Shkreli on five...

Tagged in: Pharma Fraud,

Celgene to Pay $280M to Resolve Fraud Allegations

Posted 07/26/17

By the C|C Whistleblower Lawyer Team Pharmaceutical manufacturer Celgene Corp. agreed to pay $280 million to settle claims that it illegally promoted two cancer drugs, Thalomid and Revlimid, for unapproved uses. The case was filed by a former Celgene sales representative under the False Claims Act, which allows individuals to sue to recover government dollars and share in any recovery. The New York Times reports...

Tagged in: Anti-Kickback and Stark, FCA Federal, FCA State, Healthcare Fraud, Medicaid, Medicare, Off-Label and Unapproved Use, Pharma Fraud, Whistleblower Case, Whistleblower Rewards,

Ninth Circuit Finds Materiality in the Face of Continued Government Payment

Posted 07/14/17

By Rosie Dawn Griffin Earlier this month, the U.S. Court of Appeals for the Ninth Circuit revived United States ex rel. Campie v. Gilead Scis., a False Claims Act (FCA) suit against pharmaceutical giant Gilead Sciences and, in doing so, provided the qui tam bar with additional guidance on how the lower courts will interpret the Supreme Court’s emphasis on materiality in Universal Health Services, Inc. v....

Tagged in: FCA Federal, FCA Materiality, FDA Fraud, Other Government Health Programs, Pharma Fraud, Whistleblower Case,

U.S. Charges 412, Including Doctors, in $1.3 Billion Health Fraud

Posted 07/14/17

By the C|C Whistleblower Lawyer Team Hundreds of people nationwide, including dozens of doctors, have been charged in health care fraud prosecutions, accused of collectively defrauding the government of $1.3 billion. Nearly one-third of the 412 charged were accused of opioid-related crimes. The health care providers, about 50 of them doctors, billed Medicare and Medicaid for drugs that were never purchased;...

Tagged in: Healthcare Fraud, Pharma Fraud,

Fraudster of the Week -- "Pharma Bro" Martin Shkreli

Posted 06/30/17

By the C|C Whistleblower Lawyer Team On Wednesday, opening statements were delivered in the trial of Martin Shkreli, the “pharma bro” who is best known for his fiftyfold price increase of the lifesaving HIV/AIDS drug Daraprim while CEO of Turing Pharmaceuticals. Shkreli is being tried, however, on several counts of securities and wire fraud dating from his time running the hedge funds MSMB Capital and MSMB...

Tagged in: Catch of the Week, Pharma Fraud,

Contact

Click here for a confidential contact or call:

Aegerion Pharmaceuticals Will Pay More Than $40 Million to Resolve Investigations Into Its Marketing and Sales Practices

Health Insurers May Be Contributing to the Opioid Crisis in the United States

DOJ Catch of the Week -- Novo Nordisk Inc.

Mylan Agrees to Pay $465 Million in a False Claims Act Settlement

DOJ Catch of the Week -- Mylan

Martin Shkreli is Found Guilty of Fraud

Celgene to Pay $280M to Resolve Fraud Allegations

Ninth Circuit Finds Materiality in the Face of Continued Government Payment

U.S. Charges 412, Including Doctors, in $1.3 Billion Health Fraud

Fraudster of the Week -- "Pharma Bro" Martin Shkreli

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: